Outcome Validation of the Beckman Coulter Access Analyzer in a Second-Trimester Down Syndrome Serum Screening Application | Zendy

Andrew R. MacRae | Zendy; Humphrey Gardner | Zendy; Lynn C. Allen | Zendy; Sonya Tokmakejian | Zendy; Nathalie Lepage | Zendy

Open Access

Outcome Validation of the Beckman Coulter Access Analyzer in a Second-Trimester Down Syndrome Serum Screening Application

Author(s) -

Andrew R. MacRae,

Humphrey Gardner,

Lynn C. Allen,

Sonya Tokmakejian,

Nathalie Lepage

Publication year - 2003

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/49.1.69

Subject(s) - medicine , human chorionic gonadotropin , obstetrics , estriol , gestational age , pregnancy , gynecology , endocrinology , biology , hormone , genetics

Mid-trimester maternal serum alpha-fetoprotein (AFP) and unconjugated estriol (uE3) are 30% lower and human chorionic gonadotropin (hCG) is twofold higher in Down syndrome pregnancies compared with unaffected pregnancies. In maternal serum screening, patient-specific risks are calculated using published gaussian frequency distribution parameters for these three markers obtained with previously available immunoassays. New immunoassays must generate similar distribution parameters if the accuracy of assigned risks and overall performance of prenatal screening are to be maintained.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research